# An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

> **NCT05952557** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 5500 (estimated)

## Conditions studied

- Breast Cancer, Early Breast Cancer

## Interventions

- **DRUG:** Camizestrant
- **DRUG:** Tamoxifen
- **DRUG:** Anastrozole
- **DRUG:** Letrozole
- **DRUG:** Exemestane
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT05952557
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-05
- **Primary completion:** 2030-03-04
- **Final completion:** 2037-05-06
- **Target enrollment:** 5500 (ESTIMATED)
- **Last updated:** 2025-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05952557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05952557, "An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05952557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*